Welcome to LookChem.com Sign In|Join Free
  • or
HENAN SUNLAKE ENTERPRISE CORPORATIONNeratinib//file1.lookchem.com/cas/reactions/2021/07/05/9971763.png
qq

Communicate with Supplier:

Ms. summer
Ms. summer: What can I do for you?

Neratinib CAS NO.698387-09-6

Min.Order Quantity:
100 Gram
Purity:
99%
Port:
Any Chinese main ports
Payment Terms:
L/C,D/A,D/P,T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

  • neratinib
  • HIGH purity by own lab 698387-09-6
  • Unii-jjh94R3pwb

Quick Details

  • ProName: Neratinib
  • CasNo: 698387-09-6
  • Molecular Formula: C30H29ClN6O3
  • Appearance: white to brown low melting crystallin...
  • Application: 698387-09-6 Neratinib (HKI-272) is a...
  • DeliveryTime: Within 7 working days since received y...
  • PackAge: 1g;5g;10g;25g;50g;100g;500g;1KG;5KG,25...
  • Port: Any Chinese main ports
  • ProductionCapacity: 100 Kilogram/Month
  • Purity: 99%
  • Storage: 2-8, cold storage, to avoid light stor...
  • Transportation: BY SEA /BY AIR /BY COURIER
  • LimitNum: 100 Gram
  • Heavy metal: NULL
  • Grade: Industrial Grade,Food Grade,Pharma Gra...
  • Valid Period: 6 month
  • Application: Multipurpose intermediate
  • Certification: ISO/9001 Certificate

Superiority

neratinib basic information
new anticancer drug synthesis pathways side effect
product name: neratinib
synonyms: (2e)-n-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;neratinib;(e)-n-[4-[3-chloro-4-[(2-pyridinyl)methoxy]anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide;(2e)-n-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;n-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide;unii-jjh94r3pwb;neratinib(hki-272);(2e)-n-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
cas: 698387-09-6
mf: c30h29cln6o3
mw: 557.04266
einecs:
product categories: antineoplastic;anti-cancer & immunity;inhibitors
mol file: 698387-09-6.mol
neratinib structure
neratinib chemical properties
density 1.33
safety information
msds information
neratinib usage and synthesis
new anticancer drug neratinib developed by us wyeth company is an irreversible epidermal growth factor receptor(egfr) inhibitor. it is a multiple target point of small molecule tyrosine kinase inhibitors to her 2 and her1 after lapatinib, and is an irreversible erbb receptor tyrosine kinase inhibitor. neratinib could selectively inhibit her-1 and her-2 of egfr family(ic50 was 92 nmol/l and 59 nmol/l, respectively). clinical research showed that neratinib exerted significant therapeutic effect on non-small cell lung cancer, colon cancer, and breast cancer.
the phaseⅱclinical trial indicated that neratinib showed good efficacy and tolerance to her-2 positive patients with advanced breast cancer who had been received or not trastuzumab treatment.
the phase ⅲ breast cancer clinical trial was complete in september 2014. the data indicated that the efficacy of neratinib was better than roche's herceptin in treatment of her-2 positive early breast cancer.
the above information is edited by the chemicalbook of liu yujie.
synthesis pathways 3-chloro-4- (pyridin-2-yl-methoxy) - aniline (2) and n- (4- chloro-3-cyano-7-ethoxy-quinolin-6-yl) - acetamide (3) are used as raw material to prepare n- [4- [3- chloro-4- (pyridin-2-yl-methoxy) anilino] -3-cyano-7-ethoxy-quinolin-6-yl] acetamide (4) by nucleophilic substitution. deprotection of 4 was under the effect of hydrochloric acid, then was precipitated the free base in methanol solution of potassium carbonate to prepare 6-amino-3-cyano-4- [3-chloro-4- (pyridin-2-yl-methoxy) anilino] -7-ethoxy-quinoline (5). neratinib(1) was obtained by condensation of 5 and acyl chloride which was prepared by trans-4-dimethylamino-crotonic acid hydrochloride (6).
synthesis pathways of neratinib
figure 1 synthesis pathways of neratinib
side effect diarrhea, nausea, vomiting, and fatigue.
usage neratinib (hki-272) is a highly selective her2 and egfr inhibitor with ic50 of 59 nm and 92 nm, respectively.
usage an oral, irreversible dual egfr/her2 inhibitor for breast and non-small cell lung cancer. antitumor agent

service we provide:

1. mixed container, we can mix different items in one container.

2. quality control, before shipment, free sample for test. after shipment, keep sample for 3 years

3. prompt shipment with professional documents

4. packing as your request, with photo before shipment

Details

  • exhibition in shanghai

we have clients throughout the world：

professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet your desire.

our laboratoy

we have our own independent lab test center：

this makes sure that our technology support is reliable and authoritative.all of self-owned fine chemicals are manufactured strictly in accordance with international standard.,and also has scientific cooperation with local colleges and institutes.

our factory

high quality with competitive price：

we are manufacturer and can provide high quality products with factory price

package & shipment

fast and safe delivery：

parcels can be sent out within 24 hours after payment. tracking number is available

secure and discreet shipment. you have various choices of transportation methods

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

Related Products

Related Keywords

Inquiry Cart 0